Neurocrine Biosciences Q4 Earnings Preview: What To Expect After The New Drug Approval
Neurocrine's pipeline includes 12 clinical programs, with two Phase 3 trials due to report in 2025. See why I rate NBIX stock a buy.
Neurocrine Biosciences Inc (NBIX) Q4 2024 Earnings Call Highlights: Record INGREZZA Growth and ...
Neurocrine Biosciences Inc (NBIX) reports robust sales growth and strategic investments amid competitive pressures and payer challenges.
Neurocrine Biosciences (NBIX) Q4 Earnings and Revenues Lag Estimates
Neurocrine (NBIX) delivered earnings and revenue surprises of -35.90% and 0.16%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Neurocrine Biosciences, Inc. (NBIX) Q4 2024 Earnings Call Transcript
Neurocrine Biosciences, Inc. ( NASDAQ: NBIX) Q4 2024 Earnings Conference Call February 6, 2025 4:30 PM ET Todd Tushla - Vice President of Investor Relations Kyle Gano - Chief Executive Officer Matt Abernethy - Chief Financial Officer Eric Benevich - Chief Commercial Officer Eiry Roberts - Chief Medical Officer
Neurocrine: Q4 Earnings Snapshot
SAN DIEGO (AP) — SAN DIEGO (AP) — Neurocrine Biosciences Inc. (NBIX) on Thursday reported fourth-quarter earnings of $103.1 million. The San Diego-based company said it had profit of $1 per share.
Earnings Summary: Neurocrine Biosciences Q4
Neurocrine Biosciences missed estimated earnings by -1.0%, reporting an EPS of $1.69 versus an estimate of $1.71. Revenue was up $112.50 million from the same period last year. During the previous quarter, the company beat on EPS by $0.3, leading to a 3.0% drop share price change the next day.
Neurocrine Biosciences Inc Q4 Profit Decreases, Misses Estimates
Neurocrine Biosciences Inc (NBIX) reported earnings for fourth quarter that decreased from the same period last year and missed the
Neurocrine Biosciences targets $2.5B-$2.6B INGREZZA sales for 2025 amid expanded sales force
Q4 2024 Management View CEO Kyle Gano highlighted Neurocrine's transformation into a fully integrated biopharmaceutical company. He emphasized the strong performance of INGREZZA, which is poised for ...
Neurocrine reports Q4 adjusted EPS $1.69, consensus $1.93
Reports Q4 revenue $627.7M, consensus $629.44M. “I’m proud of the tremendous progress we made last year with the continued growth of INGREZZA ...
American Association of Individual Investors12h
Which Is a Better Investment, Biogen Inc. or Neurocrine Biosciences, Inc. Stock?
Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.
Hosted on MSN10h
Neurocrine Crumbles On Lackluster Guidance For Its Bread-And-Butter Drug
Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.
Neurocrine sees FY25 Ingrezza net product sales $2.5B-$2.6B
FY25 revenue consensus $2.79B.Maximize Your Portfolio with Data Driven Insights:Leverage the power of TipRanks' Smart Score, a data-driven tool ...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Tokio Marine Asset Management Co. Ltd.
Tokio Marine Asset Management Co. Ltd. cut its holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Free Report) by 2.8% ...
Neurocrine Biosciences Stock: A Deep Dive Into Analyst Perspectives (7 Ratings)
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $169.43, a high estimate of $190.00, and a low estimate of $148.00. Observing a ...
Neurocrine price target raised to $184 from $182 at BofA
BofA raised the firm’s price target on Neurocrine (NBIX) to $184 from $182 and keeps a Buy rating on the shares. The firm, which highlights ...